Biohaven Pharmaceutical Hld

Biohaven Ltd. operates as a biopharmaceutical company that focuses on neurological and neuropsychiatric diseases. Its portfolio includes treatments for medical needs including focal epilepsy, obsessive compulsive disorder, spinocerebellar ataxia and spinal muscular atrophy. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -44.178% and 0.05%, respectively, for the quarter ended March 2021.

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q1 Loss, Tops Revenue Estimates (Revised)

Biohaven Pharmaceutical Holding Company Ltd (BHVN) CEO Vladimir Coric on Q1 2021 Results - Earnings Call Transcript

Shares of Biohaven Pharma Hldgs (NYSE:BHVN) fell 1.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 24.27% over the past year to ($2.97), which missed the estimate of ($2.82).

Recap: Biohaven Pharma Q1 Earnings

NEW HAVEN, Conn., May 10, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Reports First Quarter 2021 Financial Results and Recent Business Developments

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Earnings Preview: Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Q1 Earnings Expected to Decline

NEW HAVEN, Conn., April 28, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven to Report First Quarter 2021 Financial Results and Recent Business Developments on May 10, 2021

NEW HAVEN, Conn., April 13, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Highlights Neuroscience Advancements with 22 Presentations at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) witnessed a jump in share price last session on above-average trading volume.

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Stock Jumps 8.5%: Will It Continue to Soar?

NEW HAVEN, Conn., April 7, 2021 /PRNewswire/ --- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Announces Preliminary 1Q2021 Net Product Revenue For NURTEC ODT

MOORESVILLE, N.C., April 6, 2021 /PRNewswire/ -- Rick Ware Racing announced today its partnership with Biohaven's Nurtec® ODT (rimegepant) and Nine Line Apparel to honor the nation's fallen service members during the Memorial Day weekend Coca-Cola 600 at the Charlotte Motor Speedway.

Rick Ware Racing, Biohaven's Nurtec ODT and Nine Line Apparel Honor Fallen Service Members

Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) has enrolled the first patient in a Phase 2/3 trial evaluating oral zavegepant for migraine's preventive treatment, triggering a milestone funding payment of $100 million. In August last year, Biohaven entered into a funding agreement with Royalty Pharma to secure up to $250 million to advance the development of zavegepant in migraine and other CGRP-mediated diseases.

Biohaven Secures $100M Milestone Funding After Enrolling First Patient In Migraine Study With Oral Zavegepant

NEW HAVEN, Conn., March 29, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Enrolls First Patient in Phase 2/3 Trial of Oral Zavegepant, Prompting $100 Million Milestone Funding Payment from Royalty Pharma

Coupang

Keurig Dr Pepper Inc

GoHealth, Inc.

Innoviva

JOANN

Merchants Bancorp

PennyMac Financial Services

Prometheus Biosciences

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Some insiders took advantage of initial public offerings in the past week.

The Past Week's Notable Insider Buys Include Coupang, Keurig Dr Pepper, IPOs And More

NEW HAVEN, Conn., March 15, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares

Biohaven Announces Proposed Public Offering Of Common Shares

argenx

BioMarin Pharmaceutical

Mirati Therapeutics

Novo Nordisk

Novartis

Pharmaceutical stocks are a sector with unique success factors. One factor is developing blockbuster drugs.

7 Pharmaceutical Stocks Working on Their Next Blockbuster

Oracle

Tesla

American Electric Power Company

Catabasis Pharmaceuticals

Esperion Therapeutics

Restaurant Brands

Werner Enterprises

With the trading day halfway over, the broad markets were making yet another strong push.

AEP, Oracle, Tesla and More Thursday Afternoon Analyst Calls

NEW HAVEN, Conn., March 11, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven's NURTEC® ODT Approved In United Arab Emirates For Acute Treatment Of Migraine

NEW HAVEN, Conn., March 10, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Announces Completion Of 50% Enrollment Ahead Of Timelines In Verdiperstat Pivotal HEALEY ALS Platform Trial At Massachusetts General Hospital

NEW HAVEN, Conn., March 10, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven's NURTEC® ODT Approved In Israel For Acute Treatment Of Migraine

Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.

Biohaven (BHVN) Q4 Earnings Miss, Nurtec Uptake Promising

Biohaven is working on three distinct approaches to advancing its therapies, its CGRP, its Glutamate and its MPO/UC1MT platforms. Biohaven's sole approved therapy is NURTEC, from its CGRP platform for acute migraines. NURTEC has had a productive 2020 despite launching in 2020 during the pandemic.

Biohaven: Exciting Times, Lots To Prove

Agreement enables Biohaven to exercise option on up to three of Artizan's candidates for the treatment of inflammatory bowel disease

Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) CEO Vlad Coric on Q4 2020 Results - Earnings Call Transcript

Shares of Biohaven Pharmaceutical (NYSE:BHVN) decreased 0.1% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 5.61% year over year to ($2.69), which beat the estimate of ($2.97).

Recap: Biohaven Pharmaceutical Q4 Earnings

News for Biohaven Pharmaceutical Hld Stock (BHVN)